The editorial comment correctly emphasizes the inherent weaknesses of our study, which were anticipated when the study was planned. At that time, we were aware of these limitations, including the nonrandomized design and the lack of information about comorbidities, with the latter factor highly affecting the treatment choice. Nevertheless, we regard our descriptive analysis of our country's curative treatment modalities for prostate cancer as important. Also, such an analysis would at least enable subsequent studies of pattern of care of patients with nonmetastatic prostate cancer.
展开▼
